spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Plexxikon 

 HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Jun 2018
IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Oct 2016
Launch of Carrick Therapeutics Signals New Approach to Cancer Therapies
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Feb 2015
FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2014
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Sep 2014
Afferent Pharmaceuticals Names Kathleen Sereda Glaub as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 May 2014
Lightstone Ventures Closes First Fund at $172 Million
Venture Capital
 HSMN NewsFeed - 9 Jan 2014
Covidien, Lightstone Ventures, New Enterprise Associates Announce Series A Investment in FIRE1
Devices Venture Capital Personnel
 HSMN NewsFeed - 31 May 2013
Plexxikon Announces Program Update and Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2012
Kolltan Pharmaceuticals Appoints Gerald McMahon, Ph.D., President & Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Apr 2012
Syndax Pharmaceuticals Appoints Arthur M. Pappas to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Feb 2012
Plexxikon Announces European Approval of Zelboraf(R) for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Aug 2011
FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
Biopharmaceuticals Oncology Personalized Medicine FDA
 HSMN NewsFeed - 4 Apr 2011
Daiichi Sankyo Completes Plexxikon Acquisition
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Jan 2011
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
Biopharmaceuticals Diagnostics Personalized Medicine
 HSMN NewsFeed - 4 Sep 2009
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Aug 2009
Kolltan Pharmaceuticals Expands Board of Directors and Senior Executive Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Oct 2008
Pathwork Diagnostics Announces Key Additions to Management Team
Diagnostics Personnel
 HSMN NewsFeed - 15 May 2008
Proteolix Appoints Thomas Kassberg Executive Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2007
Plexxikon Expands Management Team and Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Oct 2006
CoLucid Names James F. White as President and Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 4 Oct 2006
Plexxikon and Roche Enter Partnership to Develop Targeted Cancer Therapeutic Medicine PLX4032
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Oct 2006
Plexxikon Files IND Application for Targeted Cancer Therapeutic PLX4032
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
Plexxikon and Servier Signed Cardiovascular Collaboration
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2006
Plexxikon Appoints Chief Financial Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 8

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 8 additional stories matching:
Plexxikon
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.